TY - JOUR
T1 - Risk of subsequent colorectal cancers after a solid tumor in childhood
T2 - Effects of radiation therapy and chemotherapy
AU - Allodji, Rodrigue S.
AU - Haddy, Nadia
AU - Vu-Bezin, Giao
AU - Dumas, Agnès
AU - Fresneau, Brice
AU - Mansouri, Imene
AU - Demoor-Goldschmidt, Charlotte
AU - El-Fayech, Chiraz
AU - Pacquement, Hélène
AU - Munzer, Martine
AU - Bondiau, Pierre Yves
AU - Berchery, Delphine
AU - Oberlin, Odile
AU - Rubino, Carole
AU - Diallo, Ibrahima
AU - de Vathaire, Florent
N1 - Publisher Copyright:
© 2018 Wiley Periodicals, Inc.
PY - 2019/2/1
Y1 - 2019/2/1
N2 - Background: Very few previous studies have addressed the question of colorectal cancer (CRC) after childhood cancer treatment. We aimed to quantify the roles of radiation therapy and chemotherapy agents in the occurrence of subsequent CRC. Methods: A nested case–control study was conducted using 36 CRC cases and 140 controls selected from 7032 five-year survivors of the French Childhood Cancer Survivor Study (FCCSS) cohort, treated from 1945 to 2000 in France. The radiation dose-distribution metrics at the site of CRC and doses of individual chemotherapeutic agents were calculated. Conditional logistic regressions were performed to calculate odds ratios (ORs). Results: Overall, patients who received radiotherapy with estimated dose to colon had a 4.3-fold (95% CI, 1.3–17.6) increased risk for CRC compared with patients who did not receive radiotherapy, after adjustment for chemotherapy. This risk increased to 8.9-fold and 19.3-fold among patients who received radiation doses ranging from 20 to 29.99 Gy and ≥30 Gy, respectively. Our data reported a significantly elevated OR for anthracyclines, after controlling for radiotherapy and MOPP regimen. But, restricted analyses excluding patients who had received ≥30 Gy showed that only radiation doses ranging from 20 to 29.99 Gy produced a significant increase in subsequent CRC risk (OR = 7.8; 95% CI, 1.3–56.0), after controlling for anthracyclines and MOPP regimen. Conclusions: The risk of subsequent CRC was significantly increased after radiation dose (even < 30 Gy). This novel finding supports the need to update monitoring guidelines for CRC to optimize the long-term follow-up for subsequent CRC in survivors of childhood cancer.
AB - Background: Very few previous studies have addressed the question of colorectal cancer (CRC) after childhood cancer treatment. We aimed to quantify the roles of radiation therapy and chemotherapy agents in the occurrence of subsequent CRC. Methods: A nested case–control study was conducted using 36 CRC cases and 140 controls selected from 7032 five-year survivors of the French Childhood Cancer Survivor Study (FCCSS) cohort, treated from 1945 to 2000 in France. The radiation dose-distribution metrics at the site of CRC and doses of individual chemotherapeutic agents were calculated. Conditional logistic regressions were performed to calculate odds ratios (ORs). Results: Overall, patients who received radiotherapy with estimated dose to colon had a 4.3-fold (95% CI, 1.3–17.6) increased risk for CRC compared with patients who did not receive radiotherapy, after adjustment for chemotherapy. This risk increased to 8.9-fold and 19.3-fold among patients who received radiation doses ranging from 20 to 29.99 Gy and ≥30 Gy, respectively. Our data reported a significantly elevated OR for anthracyclines, after controlling for radiotherapy and MOPP regimen. But, restricted analyses excluding patients who had received ≥30 Gy showed that only radiation doses ranging from 20 to 29.99 Gy produced a significant increase in subsequent CRC risk (OR = 7.8; 95% CI, 1.3–56.0), after controlling for anthracyclines and MOPP regimen. Conclusions: The risk of subsequent CRC was significantly increased after radiation dose (even < 30 Gy). This novel finding supports the need to update monitoring guidelines for CRC to optimize the long-term follow-up for subsequent CRC in survivors of childhood cancer.
KW - anthracyclines
KW - chemotherapy
KW - childhood cancer survivors
KW - procarbazine
KW - radiotherapy
KW - subsequent colorectal cancers
KW - vincristine
UR - http://www.scopus.com/inward/record.url?scp=85055267798&partnerID=8YFLogxK
U2 - 10.1002/pbc.27495
DO - 10.1002/pbc.27495
M3 - Article
C2 - 30345604
AN - SCOPUS:85055267798
SN - 1545-5009
VL - 66
JO - Pediatric Blood and Cancer
JF - Pediatric Blood and Cancer
IS - 2
M1 - e27495
ER -